ASX Cannabis Stock Slips Amid Ongoing FDA Approval Process - Kalkine Media

October 31, 2023 02:23 PM AEDT | By Team Kalkine Media
Follow us on Google News:

While the broader All Ordinaries Index (ASX: XAO) has shown a positive trajectory during Tuesday's lunch hour, the cannabis sector tells a different story. Two ASX-listed cannabis stocks, Little Green Pharma Ltd and Botanix Pharmaceuticals Ltd, are currently grappling with challenges, resulting in a struggle for their share prices. 

Little Green Pharma Share Price Falters Amid European Sales Slump 

Little Green Pharma (ASX: LGP), a vertically integrated medicinal cannabis business, has seen its share price decline by 3.1%, with shares trading at 15.5 cents apiece. The company recently released its quarterly updates, shedding light on its financial performance. 

Little Green Pharma reported quarterly revenue of $6.2 million, in line with the previous quarter's figures. Similarly, cash receipts remained consistent with the prior quarter at $6.6 million. Additionally, the company disclosed trade receivables of $1.8 million at the end of the quarter. 

While revenue in Australia witnessed a 5% increase quarter on quarter, a significant concern stems from the 33% decline in sales into Europe. However, the company anticipates robust demand from France, citing an additional 7,000 units of oil sent during the quarter. 

The company's balance sheet reveals cash reserves of $6.2 million and long-term debt of $3.6 million as of September 30. 

Also Read: Pros and Cons of Payday Loans Direct: What You Need to Know Before Borrowing 
ASX Cannabis Stock Slips Amid Ongoing FDA Approval Process 

Botanix Pharmaceuticals(ASX: BOT), a clinical-stage cannabinoid therapeutics company, is also experiencing a decline in its share price, down 1.8%, as a result of its quarterly update. The company had previously seen a remarkable 300% increase in its share price year to date, driven by expectations of pending United States FDA approval for its Sofpironium Bromide product, designed to treat excessive sweating. 

However, the FDA approval process hit a snag due to issues with packaging instructions, leading to a 32% slump in the share price. Despite this setback, the stock remains up 174% in 2023. 

Botanix is resubmitting for approval, with the final required component set for submission in the first quarter of 2024, targeting approval by mid-2024. Investors seem cautious about recommitting to this ASX cannabis stock until more certainty is provided by the FDA. 

In the previous quarter, Botanix raised $12.5 million through an institutional placement to both new and existing shareholders. The company's balance sheet reflects cash holdings of $6.8 million, and management anticipates an additional $2 million from the R&D tax return in November. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.



Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK